Maintaining the metabolic homeostasis of H. pylori through chronic hyperglycemia in diabetes mellitus: a hypothesis

Vasiliy Ivanovich Reshetnyak, Igor Veniaminovich Maev

Abstract
*Helicobacter pylori* (H. pylori) occurs in almost half of the world’s people, most of whom are merely carriers of this microorganism. *H. pylori* is shown to be detected more frequently in patients with diabetes mellitus (DM) than in the general population, which is accompanied by a significantly increased risk of developing *H. pylori*-associated diseases. At the same time, patients with DM uniquely show a low efficiency of eradication therapy for *H. pylori* infection. There is a relationship between the level of chronic hyperglycemia and a higher detection rate of *H. pylori* as well as a lower efficiency of eradication therapy in patients with DM. The exact mechanisms of these phenomena are unknown. The authors make a hypothesis that explains the relationship of chronic hyperglycemia to the enhanced detection rate of *H. pylori*, as well as the mechanisms contributing to the improved survival of this bacterium in patients with DM during eradication measures.

INTRODUCTION
Forty years have passed since the description of *Helicobacter pylori* (H. pylori) as a pathogen in the development of atrophic gastritis and peptic ulcer disease [1-3]. It has been shown that this bacterium occurs in almost half of the people in the world, most of whom are merely carriers of this microorganism [4,5]. In addition, many researchers have
indicated that *H. pylori* is detected more frequently in patients with diabetes mellitus (DM) than in the general population [6-11]. This is accompanied by a substantial increase in the risk of developing *H. pylori*-associated diseases [6,11,12]. At the same time, scientific literature has works that consider the reverse situation: the incidence of type 2 DM (T2DM) in *H. pylori*-positive patients [13-15]. However, the relationship between *H. pylori* infection and the risk of developing T2DM remains controversial and ambiguous. Hence, a prospective cohort study by Jeon *et al* has shown that *H. pylori* infection correlates with a high risk of T2DM [16]. Similarly, a meta-analysis carried out by Mansori *et al* suggests that *H. pylori* may be one of the risk factors for T2DM [11]. On the contrary, other studies report that *H. pylori* is not associated with either insulin resistance or the prevalence of T2DM [17-20]. Data from Tamura *et al* suggest that East Asian CagA-positive *H. pylori* infection is not a risk factor for T2DM [21]. At the same time, the successful *H. pylori* eradication rates in patients with type 1 and type 2 DM are 62% and 50% respectively, which is much lower than those in people who do not suffer from these two forms of the disease [22-25]. The low efficiency of eradication therapy for *H. pylori* infection in diabetic patients is uniquely presented in many works [26-29].

There is a clear correlation between the higher detection rate of *H. pylori* in diabetic patients and their lower eradication therapy, depending on the level of hyperglycemia [10,13,29]. Uncontrolled diabetes with the development of chronic hyperglycemia causes a number of metabolic changes [30]. Chronic hyperglycemia in turn leads to increased susceptibility to infective agents in diabetic patients [9,10,30,31]. The exact mechanisms that link chronic hyperglycemia and the higher detection rate of *H. pylori*, as well as the mechanisms that improve the survival of this bacterium in diabetic patients during eradication measures remain unknown. An understanding of how chronic hyperglycemia is related to the maintenance of the metabolic homeostasis of *H. pylori* for its vital activity and reproduction in diabetic patients is of great scientific and practical importance.
It is proposed to consider one of the possible hypothetical mechanisms for the impact of chronic hyperglycemia on:

- the increased detection rate of *H. pylori*;
- possible metabolic changes in the bacterial cell in the event of chronic hyperglycemia;
- the importance of hyperglycemia control on the results of eradication therapy.

It is well known that *H. pylori colonizes the gastric mucosa*. To establish long-term colonization, the bacterium must sense and adapt to the nutritional conditions that exist in its *habitat*. Surprisingly, few people pay attention to the preferred sources of nutrients and energy for the life, growth, and reproduction of *H. pylori*. Surprisingly, few people pay attention to the preferred sources of nutrients and energy for the life, growth, and reproduction of *H. pylori*. And nobody considers changes in the sources of food ingredients and energy for *H. pylori* that may occur in diabetic patients. The available data suggest that for its life, growth, and reproduction, *H. pylori* utilizes amino acids and carboxylic acids, which are produced in sufficient quantities in the stomach as a result of hydrolysis of food proteins [32–34]. *H. pylori* catabolizes a large number of amino acids with the most substantial being alanine, arginine, asparagine, aspartate, glutamate, glutamine, proline, and serine [32,33-37]. *H. pylori* can also catabolize fumaric acid [38], malic acid [38], and lactic acid [39]. As this takes place, amino acids and carboxylic acids are sources of carbon, nitrogen, and energy.

In a healthy individual, the *H. pylori* bacterium is almost independent of sugars, such as glucose [32–34]. However, glucose is known to be one of the most important carbohydrates, which is used for life by many microorganisms, including inhabitants in the digestive system. Moreover, Wang et al. [40] believe that glucose plays a key role in the outcome of a bacterial infection in humans. A question is raised as to whether *H. pylori* can utilize glucose as a plastic and energy material. Studies conducted in the 1990s and later indicate that *H. pylori* has enzyme systems capable of utilizing carbohydrates, D-glucose in particular [41-43]. These data suggest that in its evolutionary
phylogenetic development and adaptation to life and reproduction in the stomach, the *H. pylori* bacterium not only has acquired the ability to restructure its metabolism for the use of amino acids as a plastic and energy material, but has most probably retained the ability to utilize carbohydrates for their life activity. There are experimental data showing that adding glucose to the nutrient medium when growing *H. pylori*, enhances its growth [29,41].

Chronic hyperglycemia in diabetic patients includes compensatory mechanisms aimed at normalizing the blood level of glucose [5]. To remove excess glucose in patients with DM and chronic hyperglycemia, it is most likely that the extradigestive (excretory) function of the gastric mucosa is switched on. This leads to the fact that in patients with DM and chronic hyperglycemia, *H. pylori* gains advantages for its growth, reproduction, and survival, as it can use not only amino acids for its life, but also glucose available in excess in patients with DM. This hypothetical may explain the more frequent detection of *H. pylori* in patients with DM than in the general population.

Based on this assumption (hypothesis), it is possible to explain also the data on the lower efficiency of eradication therapy in patients with DM. *H. pylori* eradication regimens contain antibacterial drugs (clarithromycin, metronidazole, bismuths, etc.) and agents that reduce hydrochloric acid production. The use of antacids is aimed at creating optimal conditions for acid-dependent antibacterial agents [45-48]. The data presented in recent studies suggest that it is extremely important to determine gastric pH for *H. pylori* eradication [45,46]. At the same time, the antacids have a double effect on *H. pylori* with an opposite effect. Increased gastric pH is a favorable factor for the vital activity of *H. pylori*. But at the same time, the antacids deprive *H. pylori* of nutrients. Exposure to hydrochloric acid in the stomach causes denaturation of food proteins and initiates their hydrolysis by the gastric juice enzymes pepsin and gastrixin. This gives rise to oligopeptides with different lengths and to a certain number of amino acids, which are utilized by *H. pylori* for its life activity. Taking antacids practically does not lead to denaturation of food proteins. As a consequence, the rate of protein hydrolysis is considerably reduced. As a result, the stomach
practically does not produce amino acids that are essential for maintaining the vital activity of *H. pylori*. The lack of nutrients and the intake of antibacterial drugs result in the death of the microorganism or in its transition to a dormant form \[^{49}\]. The latter is rare during powerful antibiotic therapy.

There is an opportunity for *H. pylori* to utilize glucose as an energy and plastic material in diabetic patients receiving eradication therapy against the background of chronic hyperglycemia and amino acid deficiency. It is likely that this mechanism and enables this microorganism to successfully survive the extreme conditions of eradication. But this can happen only in the presence of chronic hyperglycemia. That is to say, the survival of *H. pylori* under extreme conditions of eradication should depend on the level of hyperglycemia. And the longer the period of hyperglycemia with its high level is, the more likely *H. pylori* is to survive the extreme conditions of eradication.

Chronic hyperglycemia can be assessed by the blood level of glycated hemoglobin A (HbA1c). The HbA1c level is the result of nonenzymatic glycosylation of hemoglobin, with the formation of a bond between glucose and the free N-terminal proline amino group in the hemoglobin β-chain \[^{50}\]. The indicator plays an important role in monitoring the time course of changes in blood glucose levels in diabetic patients and for evaluation of the efficacy of hypoglycemic drugs \[^{51}\]. In 2011, the World Health Organization officially recommended an HbA1c level of ≥6.5% as a diagnostic cut-off value for DM \[^{52}\]. This indicator reflects the integrated blood glucose level for the last 3-4 mo \[^{53-55}\]. The association between *H. pylori* infection and HbA1c in diabetic patients has been confirmed in many studies \[^{51,56,57}\]. Glycated hemoglobin A levels were significantly higher in patients with DM and *H. pylori* infection than in those with DM and without *H. pylori* infection (WMD = 0.50, 95% CI: 0.28-0.72, P<0.001) \[^{59}\]. Subgroup analysis by the subtype of DM has revealed a correlation between *H. pylori* infection and an elevated glycated hemoglobin A level in type 1 DM (I²=74%, P<0.001, WMD=0.46, 95% CI: 0.12-0.80) and in T2DM (I²=90%, P<0.001, WMD=0.59, 95% CI: 0.28-0.90, P<0.001) \[^{51}\].
In work, Bektemirova et al. used the HbA1c level to evaluate the efficacy of hypoglycemic drugs taken by 83 patients with T2DM and *H. pylori*-associated diseases during eradication therapy. Glycated hemoglobin A was shown to reach a target level of <6.5% in 62 out of the 83 examinees, while it remained elevated (>7.0%) in 21 patients. This means that despite the use of hypoglycemic drugs, the level of hyperglycemia persisted in these patients for at least 2-3 mo. And it was in these patients who did not reach the target HbA1c level had a significantly (P < 0.017)lower efficiency of eradication therapy than those who achieved the target level of HbA1c<6.5%. The data obtained by Bektemirova et al. indirectly suggest that the bacterium *H. pylori* most likely took advantage of chronic hyperglycemia to survive under the extreme conditions of eradication.

According to Tseng, the use of insulin to normalize blood glucose levels in patients with T2DM substantially increases the rate of *H. pylori* eradication compared to those with DM without insulin. The higher efficiency of *H. pylori* eradication in T2DM patients taking insulin assumes that these patients are more likely to normalize their blood glucose levels during insulin therapy. And this is most likely to cause an increase in the efficiency of *H. pylori* eradication.

**CONCLUSION**

**Conclusion.** The data available in the literature allow advance the following hypothesis that in diabetic patients, the *H. pylori* bacterium is most likely to utilize both amino acids and glucose for its vital activity. The hypothesis makes it possible to explain the high detection rate of *H. pylori* in diabetic patients, as well as their lower eradication therapy efficiency. Undoubtedly, this hypothesis requires further confirmations, by using biochemical, microbiological, molecular genetics, and other studies. Further multicenter studies are needed to confirm this hypothesis. But if this hypothesis is correct, then before *H. pylori* is eradicated in patients with diabetes mellitus, there is a need for mandatory monitoring and targeted correction of blood glucose and HbA1c levels according to the algorithm given in the figure.
The algorithm provides for the management of patients with DM and concomitant *H. pylori*-associated diseases, which is of great practical importance for their successful eradication therapy.

**ACKNOWLEDGEMENTS**

The authors express their gratitude to Alexandr Igorevich Burmistrov for technical assistance in preparing this article.
<table>
<thead>
<tr>
<th>#</th>
<th>Primary Source</th>
<th>Match Count</th>
<th>Similarity %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>doaj.org</td>
<td>79</td>
<td>4%</td>
</tr>
<tr>
<td>2</td>
<td><a href="http://www.biorxiv.org">www.biorxiv.org</a></td>
<td>32</td>
<td>1%</td>
</tr>
<tr>
<td>3</td>
<td>Takashi Tamura, Emi Morita, Sayo Kawai, Tae Sasakabe et al. &quot;No association between Helicobacter pylori infection and diabetes mellitus among a general Japanese population: a cross-sectional study&quot;, SpringerPlus, 2015</td>
<td>24</td>
<td>1%</td>
</tr>
<tr>
<td>4</td>
<td><a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a></td>
<td>14</td>
<td>1%</td>
</tr>
</tbody>
</table>